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Abstract
Current data suggest that phospholipid transfer protein (PLTP) has multiple metabolic functions, however, its physiological significance in
humans remains to be clarified. To provide further insight into the role of PLTP in lipoprotein metabolism, plasma PLTP activity was
measured, and lipoproteins were analyzed in 134 non-diabetic individuals on a controlled diet. Insulin sensitivity index (Si) and body fat
composition were also determined. Plasma PLTP activity was comparable between men (n = 56) and women (n = 78). However, in women
but not in men, plasma PLTP activity was positively correlated with cholesterol, triglyceride, low density lipoprotein (LDL) cholesterol, and
apolipoprotein (apo) B (r= 0.38–0.45, PV 0.001), and with body mass index (BMI), subcutaneous and intra-abdominal fat (SCF, IAF)
(r = 0.27–0.29, P< 0.02). Among the different apo B-containing lipoproteins (LpB) in women, PLTP was most highly correlated with
intermediate density lipoproteins (IDL) and buoyant LDL (r = 0.45–0.46, P< 0.001). The correlation with IDL was significant only in
women with BMI V 27.5 kg/m2 (n = 56). In men with BMI V 27.5 kg/m2 (n = 35), PLTP activity was significantly correlated with buoyant
LDL (r = 0.40, P< 0.02) and high density lipoprotein (HDL) (r= 0.43, P < 0.01). These data provide evidence for a role of PLTP in LpB
metabolism, particularly IDL and buoyant LDL. They also suggest that gender and obesity-related factors can modulate the impact of PLTP
on LpB. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Human plasma phospholipid transfer protein (PLTP) was
initially described as a lipid transfer protein that facilitates the
transfer of phospholipids from very low density lipoproteins
(VLDL) to high density lipoproteins (HDL) [1,2]. Sub-
sequent studies demonstrated that PLTP could also promote
the conversion of HDL into larger and smaller particles,
generating pre-beta HDL in this process [3–5]. These in
vitro observations suggest a role of PLTP in triglyceride-rich
lipoprotein and HDLmetabolism. Indeed, introduction of the
human PLTP transgene with minimal expression of human
PLTP in mice increased the ratio of HDL cholesterol to low
density lipoprotein (LDL) cholesterol [6]. In transgenic and
adenovirus-infected mice overexpressing human PLTP, alpha
HDL decreased and pre-beta HDL levels increased [7,8]. Pre-
beta HDL also increased in mice expressing both human
PLTP and apolipoprotein (apo) A-I [9]. In PLTP gene knock-
out mice, minimal transfer of phospholipid and cholesterol
occurred between VLDL, LDL and HDL resulting in marked
reduction in apo A-I and HDL lipids, and VLDL and LDL
enriched with phospholipid and free cholesterol were ob-
served when these mice were fed a high fat diet [10].
While gene targeting confirms the importance of PLTP-
mediated phospholipid and cholesterol transfer in lipoprotein
metabolism, the specific physiological roles and clinical
significance of PLTP in humans remain to be clarified.
One approach to gain more insight into PLTP’s metabolic
role is to assess PLTP activity in different physiological and
pathological states, and study its association with various
metabolic parameters. It has been reported that PLTP activity
increases with age [11], obesity and insulin level [12–14],
cigarette smoking [15], alcohol abuse [16], and fat-loading
[17]. Its activity can also be affected by the fatty acid
contents of the diet. Subjects consuming diets high in trans
fatty acid [18] or lauric acid [19] have higher plasma PLTP
activity than those on diets high in dairy-fat [18] or in
palmitic acid [19], respectively. Patients with insulin-de-
pendent or non-insulin-dependent diabetes mellitus have
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higher PLTP activity than non-diabetic controls [20–22].
PLTP can facilitate the transfer of alpha tocopherol from
HDL or albumin to oxidized LDL and endothelial cells, and
prevent rabbit aortic endothelial dysfunction ex-vivo [23,24].
Furthermore, PLTP has been shown to enhance the removal
of cholesterol and phospholipid from cholesterol-loaded cells
[25], and it can transfer lipopolysaccharide from gram-
negative bacteria to HDL [26,27]. Thus, PLTP appears to
play multiple roles in lipid metabolism; it may modulate
inflammatory response and may have a modifying role in
atherogenesis [28,29].
To understand the regulatory role of PLTP on the different
density classes of lipoproteins, several research groups
including our own have analyzed the interrelationship
between plasma PLTP level and VLDL, LDL, or HDL. We
found that in a group of 52 predominantly male patients with
low HDL and cardiovascular disease, PLTP activity was
associated significantly with HDL parameters but not with
non-HDL parameters [30]. However, in 50 premenopausal
women, both LDL and HDL cholesterol were significantly
correlated with PLTP activity, the correlation being stronger
with the former [14]. Other investigators have also reported
differences in the association of PLTP activity with the major
lipoprotein classes. For example, in 8 obese and 24 non-
obese men [12], and in 21 normolipidemic male smokers
[15], PLTP activity was associated with non-HDL but not
HDL cholesterol. In contrast, in 400 healthy Finnish indi-
viduals, PLTP activity was associated with neither LDL nor
HDL, but with total cholesterol and triglyceride [11]. These
observations suggest the complexity in delineating the phys-
iological role of PLTP in lipoprotein metabolism in humans,
beyond what has been revealed with in vitro studies, and in
animal models. We hypothesize that some of the complexity
may be attributed to metabolic differences among individu-
als. To test this hypothesis, we measured the PLTP activity in
134 well-defined subjects who have been stabilized on a
controlled diet, and studied its association with the multiple
lipoprotein fractions separated by density gradient ultracen-
trifugation. We also determined the impact of gender and
metabolic factors such as body fat and insulin sensitivity on
PLTP activity and on the relationship between PLTP and
lipoproteins. In these subjects, we found that PLTP was
highly associated with LDL, and this association was dis-
tinctly confined to buoyant but not dense LDL. Furthermore,
the impact of PLTP on these lipoproteins can be modified by
adiposity and other gender-related factors.
2. Methods
2.1. Subjects and blood samples
The 134 subjects (56 men and 78 women) in this study are
a random subset of participants in a dietary study designed to
determine the relationship of insulin sensitivity and obesity
status to an individual’s responsiveness to dietary cholesterol
from eggs. Subjects were recruited from radio and newspaper
advertisements and posters. Inclusion criteria were: age 25–
75 years, fasting glucose by fingerstick less than 110 mg/dl;
no proteinuria by dipstick; fasting LDL-cholesterol less than
190 mg/dl and triglyceride < 500 mg/dl; no uncontrolled
hypertension (blood pressure > 150/100); no lipid-altering
medications such as cholesterol lowering drugs, oral contra-
ceptives, beta-blockers, thiazides; no history of coronary,
vascular, renal, liver, or unstable thyroid disease or diabetes
mellitus; no history of mental illness or alcohol intake greater
than two drinks per day. Thyroid hormone and estrogen
replacement therapies were allowed. All subjects attended
an initial orientation and signed a consent form approved by
the Human Subject Review Committee of the University of
Washington. They were counseled to adhere to the National
Cholesterol Education Program (NCEP) Step One diet [31]
( < 30% of calories from fat, < 10% from saturated fat, < 300
mg cholesterol per day), and were taught how to keep a 3-day
food record [32]. Blood used in this study was the baseline
sample drawn after the subjects had been stabilized on the
NCEP diet for 6–8 weeks prior to their randomization into
the egg-consumption phase. Venous blood was drawn into
EDTA-containing tubes after a 12–14-h overnight fast.
Plasma was promptly separated by low-speed centrifugation
at 4 jC and used for lipid and lipoprotein analyses, or frozen
at  70 jC for PLTP activity and apolipoprotein measure-
ments and for lipoprotein fractionation.
2.2. Assessment of insulin sensitivity and body composition
A frequently sampled intravenous glucose tolerance test
(IVGTT) [33] was used to determine the insulin sensitivity
index (Si) of each subject 4–8 weeks after dietary instruc-
tion prior to the visit for baseline blood draw. Subjects
consumed 150+ g of carbohydrates for the preceding 3 days,
and 32+ oz water the preceding day. The IVGTT consisted
of the collection of basal samples after an overnight fast,
followed by IV injection of 11.4 g/m2 glucose over 60 s
commencing at time zero. At 20 min, 125 mg/m2 tolbuta-
mide was administered over 30 s. Thirty-two blood samples
for glucose and insulin measurements were collected over a
4-h period after glucose administration at 2, 3, 4, 5, 6, 8, 10,
12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80,
90, 100, 120, 140, 160, 180, 200, 220, and 240 min. The Si
was obtained by identification of minimal model parameters
using a nonlinear least square technique [33]. Intra-abdomi-
nal fat (IAF) and subcutaneous fat (SCF) were assessed the
same day by cross-sectional computed tomography (CT) at
the level of the umbilicus as described [34], and is expressed
as fat area in square centimeters. All CT measurements were
performed by a single observer.
2.3. Lipoprotein fractionation
Plasma lipoproteins with different buoyancy were frac-
tionated by a nonequilibrium density-gradient ultracentrifu-
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gation (DGUC) procedure designed to maximize the sepa-
ration of the different density classes of apo B-containing
lipoproteins (LpB) [35]. LDL flotation rate is stable for at
least 29 months for plasma stored at  70 jC [35]. The
procedure involved using 1 ml of plasma sample adjusted to
5 ml of 1.08 g/ml solution with aqueous KBr (d = 1.21 g/ml)
and NaCl (d = 1.006 g/ml). This solution was under-layered
onto 12.75 ml of a 1.006 g/ml solution in a polyallomer
ULTRACRIMPk tube (DuPont) to form a discontinuous
salt gradient, and centrifuged in a Sorvall TV-865B rotor at
60,000 rpm for 105 min at 5 jC. While maintaining the cold
temperature, the tube was drained from the bottom at a flow
rate of 1.0 ml/min into 38 fractions. The cholesterol content
of each fraction was measured and a cholesterol profile was
generated to represent the distribution of plasma lipopro-
teins in each sample.
2.4. PLTP activity
The plasma phospholipid transfer activity mediated by
PLTP was determined by measuring the transfer of [14C]
phosphatidylcholine from phospholipid liposomes to HDL
using an established radioassay [36]. The plasma samples
were assayed in triplicate. Three plasma control samples,
flash-frozen and stored at  70 jC until use, were included
in each assay to control for inter-assay variation.
2.5. Other laboratory measurements
Standard enzymatic methods performed on an Abbott
Spectrum Bichromatic Analyzer were used to determine
glucose, cholesterol, triglyceride, and phospholipid [37] in
plasma and in fractionated lipoproteins. Plasma HDL choles-
terol concentration was measured from the supernatant frac-
tion, following precipitation of LDL and VLDL by dextran
sulfate and magnesium chloride [38]. Cholesterol in VLDL
and LDL was calculated using the Friedewald equation [39].
Apo A-I and apo B were measured with a Behring nephel-
ometer using Behring reagents (Behring Diagnostic, Inc.,
Somerville, NJ) and calibrated with the Northwest Lipid
Research Laboratories calibrator. Total immunoreactive insu-
lin was measured by a standardized double-antibody radio-
immunoassay in the Diabetes Endocrinology Research
Center at the University of Washington [40].
2.6. Statistical analysis
Statistical differences between subject groups were as-
sessed using the Mann–Whitney U test. Spearman rank
order correlation analyses were used to determine the meta-
bolic and lipoprotein parameters associated with PLTP
activity, and subsequent forward stepwise linear regression
analysis was used to identify the independent variables
among the parameters that contributed to the variation in
PLTP activity. Plasma triglyceride, IAF, SCF, and body mass
index (BMI) were log-transformed for the linear regression
analysis. All analyses were carried out using statistical
software (Stat Soft, Tulsa, OK). In view of multiple corre-
lations, only P-values of V 0.02 (two-tailed) are reported as
significant unless otherwise indicated.
3. Results
3.1. Subject characteristics
The characteristics of the subjects are summarized in
Table 1. The subjects had normal fasting glucose by selection
criteria; however, their Si ranged from 0.4 to 18.0 10 4
min  1/(AU/ml) with 86 (46 women and 40 men) being
insulin-resistant (Si < 4.2 units). Twenty-two women and 21
men were obese, having a BMI z 27.5 kg/m2 [41]. Although
the mean lipid profile of the study population was normal,
the subjects exhibited a wide range of lipid levels with the
minimum and maximum for plasma cholesterol being 121
and 303 mg/dl, and for triglyceride being 28 and 432 mg/dl,
respectively. Among the women, 28 were premenopausal,
and not taking hormones; 50 were postmenopausal, with 30
of them taking estrogen with or without progesterone. PLTP
levels did not differ significantly among these three groups
of women.
No gender differences were observed in plasma PLTP
activity as well as in age, SCF, plasma cholesterol and
triglyceride, LDL cholesterol and apo B. However, men
had significantly lower Si (P= 0.02) and, as expected, lower
HDL cholesterol (P < 0.001) and plasma apo A-I (P < 0.001)
than women. Although men and women had comparable
total fat area by CT scan, men had significantly more IAF
(P < 0.001) (Table 1). They also had a slightly higher BMI
(P= 0.01) than women.
Table 1
Subject characteristics
All (n= 134) Women (n= 78) Men (n= 56)
Age (year) 53.0F 10.5 52.9F 9.6 53.1F11.7
BMI (kg/m2) 26.0F 4.3 25.5F 4.8 26.8F 3.6*
SCF (cm2) 207F 126 227F 146 179F 84.5
IAF (cm2) 101F 73.6 75.9F 56.2 137F 80.5**
Si [104 min1/(AU/ml)] 4.04F 2.55 4.35F 2.34 3.62F 2.79*
Triglyceride (mg/dl) 122F 78.7 118F 66.8 129F 93.0
Cholesterol (mg/dl) 200F 37.2 202F 39.6 196F 33.6
LDL cholesterol (mg/dl) 123F 30.7 122F 31.3 126F 29.9
Apo B (mg/dl) 97.2F 23.8 96.3F 24.5 98.5F 23.0
HDL cholesterol (mg/dl) 51.5F 14.4 56.8F 14.8 43.9F 10.0**
Apo A-I (mg/dl) 141F 27.4 152F 28.3 125F 16.3**
PLTP activity (Amol/ml/h) 14.5F 2.06 14.5F 1.97 14.6F 2.2
Abbreviations: BMI—body mass index; SCF—subcutaneous fat; IAF—
intra-abdominal fat; Si—insulin sensitivity index; LDL—low density
lipoprotein; HDL—high density lipoprotein; PLTP—phospholipid transfer
protein.
Numbers are meanF S.D.
* P< 0.02.
** P< 0.001 denote significant difference between men and women by
Mann–Whitney U test.
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3.2. Association of plasma PLTP activity and lipoproteins
In these 134 subjects, plasma PLTP activity was pos-
itively correlated with total and LDL cholesterol and apo B
(rz 0.24, PV 0.005) (Table 2). When the relationship
between PLTP activity and lipoproteins or metabolic param-
eters was analyzed by gender, a clear gender difference was
observed. All the above significant associations seen with
the entire study population were observed only in women
but not in men (Table 2). Furthermore, PLTP activity in
women was also significantly and positively correlated with
triglyceride (r = 0.38, P= 0.001), and with each of the in-
dexes of body fat (r = 0.27–0.29, P < 0.02).
Because PLTP activity showed the strongest relationship
with apo B in these subjects, and one of the functions of
PLTP is to transfer phospholipid from the lower density
lipoproteins to HDL, the association between PLTP and apo
B-containing lipoprotein subfractions was studied. These
lipoproteins were separated by DGUC based on their buoy-
ancy. With this method, VLDL was located in fractions 30–
38, intermediate density lipoprotein (IDL) in fractions 19–
29, LDL in fractions 7–18, and HDL in fractions 1–6 [42].
Fig. 1 shows the composite DGUC profile of the study
population and the Spearman correlation coefficient between
plasma PLTP and cholesterol in each density fraction. In
women but not in men, PLTP correlated significantly and
positively with the cholesterol content of fractions 13–38,
with the strongest correlation seen in fractions 14–25
(r = 0.40–0.56, P < 0.001), which contained IDL and buoy-
ant LDL. No consistent significant correlation was detected
between PLTP and the cholesterol content in fractions 1–12,
the fractions that contained dense LDL and HDL.
3.3. Association of IDL and buoyant LDL with lipid and
metabolic parameters
To determine if factors that contributed to the variation of
PLTP activity also contributed to the variation of IDL and
buoyant LDL level, correlation analysis was performed with
the parameters in Table 1 as independent variables and
either IDL or buoyant LDL cholesterol as the dependent
variable. As expected, both IDL and buoyant LDL were
significantly correlated with total and LDL cholesterol, and
with apo B in women (r = 0.47–0.70, P < 0.001) and in men
(r = 0.33–0.63, P < 0.02) (Table 3). In women, both were
also significantly correlated with age (rz 0.36, P= 0.001),
triglyceride (rz 0.28, P < 0.02), and PLTP activity (rz
0.45, P < 0.001). In addition, a trend of correlation was
observed between buoyant LDL and HDL cholesterol
(r = 0.24, P < 0.04), and between IDL and IAF in women
(r = 0.26, P < 0.03) (Table 3). Forward stepwise linear
regression analysis using PLTP, triglyceride, apo A-I, age,
Si, and either BMI, SCF, or IAF as independent variables,
showed that among these variables, significant independent
Table 2
Correlation between plasma PLTP activity and metabolic parameters
All (n= 134) Women (n= 78) Men (n= 56)
r P r P r P
Age 0.14 0.112 0.26 0.024 0.00 0.993
BMI 0.18 0.042 0.28 0.013 0.02 0.915
SCF 0.18 0.040 0.29 0.011 0.02 0.863
IAF 0.15 0.075 0.27 0.017  0.02 0.886
Si  0.14 0.116  0.23 0.042  0.03 0.841
Triglyceride 0.16 0.061 0.38 0.001  0.13 0.360
Cholesterol 0.25 0.003 0.41 < 0.001 0.03 0.816
LDL cholesterol 0.24 0.005 0.40 < 0.001 0.03 0.840
Apo B 0.26 0.002 0.45 < 0.001 0.02 0.914
HDL cholesterol 0.02 0.819  0.09 0.435 0.18 0.183
Apo A-I 0.06 0.518 0.03 0.794 0.15 0.278
Abbreviations and the units of the parameters are listed in Table 1. PV 0.02
are in bold font.
Fig. 1. Composite DGUC profile of the study subjects by gender. Plasma of each subject was separated into 38 fractions by DGUC as described in Methods,
and the cholesterol content in each fraction measured. The cholesterol profiles (solid line) represent the median cholesterol of each density fraction in 78
women (left) and 56 men (right) expressed as concentration in mg/dl. (.) indicates the Spearman rank correlation coefficient (r) between plasma PLTP activity
and the cholesterol in each fraction. The dotted line identifies where r reaches statistical significance at PV 0.02. The vertical lines mark the regions
corresponding to VLDL (30–38), IDL (19–29), LDL (7–18), and HDL (1–6).
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contributors of plasma IDL and buoyant LDL cholesterol
level in women were apo B, PLTP activity, and triglyceride
for IDL, and apo B, PLTP, and apo A-I for buoyant LDL. In
men, besides the parameters related to LpB (total and LDL
cholesterol and apo B), only HDL cholesterol was signifi-
cantly correlated to buoyant LDL (r = 0.37, P= 0.005).
3.4. Impact of hormonal status on the correlation between
plasma PLTP activity and lipoproteins in women
Because hormone replacement therapy is known to
increase HDL levels and reduce LDL levels, hormone
replacement therapy could alter the relationship between
PLTP activity and lipoproteins. Therefore, we evaluated the
relationship between PLTP activity and five lipoprotein
classes (VLDL, IDL, buoyant LDL, dense LDL, and HDL)
among three groups of women, premenopausal and not taking
hormones (n= 28), postmenopausal taking hormone replace-
ment therapy (n = 30), and postmenopausal not taking hor-
mones (n = 20). For this analysis, VLDL, IDL, buoyant LDL,
dense LDL, and HDL were calculated as the sum of choles-
terol in fractions 30–38, 19–29, 13–18, 7–12, and 1–6,
respectively, after DGUC. In premenopausal women and in
postmenopausal women taking hormones, PLTP activity was
significantly correlated with IDL (r = 0.43, P < 0.05 for both
groups) and buoyant LDL (r= 0.38 and 0.46, P < 0.05 and
= 0.01, respectively) (Table 4). However, in postmenopausal
women not taking hormones, the correlations between PLTP
activity and IDL (r = 0.34) and buoyant LDL (r = 0.36) were
no longer significant.
3.5. Impact of adiposity on the correlation between plasma
PLTP activity and lipoproteins
Because 21 of the 56 men (38%) were obese, we wanted to
determine if the lack of correlation between PLTP and LpB
was related to the significant presence of obese individuals in
this group of men. Table 5 shows that PLTP activity was
significantly and positively correlated with buoyant LDL
(r = 0.40,P < 0.02) andHDL (r = 0.43,P < 0.01) in non-obese
men with BMI V 27.5 (n = 34). In contrast, no significant
correlations were evident between PLTP activity and the
different lipoproteins in obese men. Likewise, PLTP activity
was significantly correlated with VLDL (r = 0.33, P < 0.02),
IDL (r = 0.49, P < 0.001), and buoyant LDL (r= 0.40, P=
0.002) in non-obese women (n = 56), but was only signifi-
cantly correlated with buoyant LDL (r = 0.54, P < 0.01) in
obese women (n = 22). Forward stepwise linear regression
analysis of the non-obese subgroups indicated a continued
difference between men and women. Significant independent
contributors of plasma IDL cholesterol level in non-obese
women were PLTP activity and apo B, while in non-obese
men PLTP activity was not a significant contributor. For
Table 3
Correlation between IDL or buoyant LDL and metabolic parameters
Women (n= 78) Men (n= 56)
IDLa Buoyant
LDLb
IDLa Buoyant
LDLb
r P r P r P r P
Age 0.36 0.001 0.37 0.001 0.06 0.662 0.17 0.209
BMI 0.18 0.120 0.08 0.488 0.05 0.704 0.24 0.075
SCF 0.26 0.021 0.25 0.027 0.15 0.278 0.12 0.389
IAF 0.26 0.024 0.20 0.082 0.06 0.689 0.08 0.561
Si 0.18 0.122 0.15 0.198 0.06 0.662 0.11 0.427
Triglyceride 0.55 <0.001 0.28 0.012 0.19 0.153 0.30 0.027
Cholesterol 0.55 <0.001 0.69 <0.001 0.34 0.011 0.53 <0.001
LDL
cholesterol
0.47 <0.001 0.70 <0.001 0.41 0.002 0.63 <0.001
Apo B 0.53 <0.001 0.57 <0.001 0.43 0.001 0.33 0.014
HDL
cholesterol
0.08 0.482 0.24 0.038 0.16 0.231 0.37 0.005
Apo A-I 0.24 0.033 0.26 0.020 0.07 0.624 0.26 0.051
PLTP activity 0.45 <0.001 0.46 <0.001 0.08 0.552 0.16 0.225
Abbreviations: IDL—intermediate density lipoprotein. See footnote of
Table 1 for all other abbreviations. PV 0.02 are in bold font.
a Sum of cholesterol in fractions 19–29 after separation of plasma by
DGUC [42].
b Sum of cholesterol in fractions 13–18 after separation of plasma by
DGUC [42].
Table 4
Impact of hormonal status on the correlation between plasma PLTP activity
and lipoproteins in women
Premenopausal Postmenopausal
No hormone
(n= 28)
On hormonea
(n= 30)
No hormone
(n= 20)
r P r P r P
VLDL 0.35 0.066 0.10 0.590 0.28 0.240
IDL 0.43 0.023 0.42 0.021 0.34 0.145
Buoyant LDL 0.38 0.048 0.46 0.010 0.36 0.115
Dense LDL 0.13 0.51 0.20 0.295 0.28 0.235
HDL 0.11 0.59 0.20 0.281 0.27 0.257
P < 0.05 are in bold font.
Very low density lipoproteins (VLDL), intermediate density lipoproteins
(IDL), buoyant low density lipoproteins (LDL), dense LDL, and high
density lipoproteins (HDL) were calculated as the sum of cholesterol in
fractions 30–38, 19–29, 13–18, 7–12, and 1–6 after these lipoproteins
were separated by DGUC.
a Postmenopausal women taking estrogen with or without progesterone.
Table 5
Impact of adiposity on the correlation between plasma PLTP activity and
lipoproteins in men and women
Body mass index
V 27.5 kg/m2
Body mass index
>27.5 kg/m2
Women
(n= 56)
Men
(n= 35)
Women
(n= 22)
Men
(n= 21)
r P r P r P r P
VLDL 0.33 0.014 0.09 0.615 0.00 0.998 0.15 0.52
IDL 0.50 <0.001 0.27 0.119 0.13 0.56 0.26 0.25
Buoyant LDL 0.40 0.002 0.40 0.018 0.54 0.009 0.21 0.35
Dense LDL 0.11 0.421 0.23 0.179 0.18 0.420 0.36 0.11
HDL 0.07 0.610 0.43 0.009 0.25 0.27 0.18 0.44
P < 0.05 are in bold font.
Abbreviations are defined in Table 4.
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buoyant LDL cholesterol levels, the only significant contrib-
utor in non-obese men was PLTP activity, while in non-obese
women the significant contributors were apo B, triglyceride,
PLTP activity, and apo A-I.
4. Discussion
Previously, we have measured plasma PLTP activity and
studied its relationship with lipids in 52 predominantly male
CVD patients with low HDL [30] and 50 healthy normolipi-
demic premenopausal women [14]. We found that plasma
PLTP activity levels were comparable between both groups
of subjects and were positively associated with HDL. In
premenopausal women a strong association between PLTP
activity and LDL was also detected. This study was carried
out to determine if these previous observations could be
extended to a larger group of men and women of a wide
age range with different lipid and metabolic characteristics,
who were participants of a dietary study. The blood samples
were obtained after the subjects had been stabilized on the
NCEP Step 1 diet for 6–8 weeks, thus minimizing possible
dietary effects on PLTP [18,19]. Mean plasma PLTP activity
(14.5 Amol/ml/h, range: 9.2 to 19.6 Amol/ml/h) of these
subjects was similar to what we reported for CVD patients
with low HDL [30] and for normolipidemic healthy preme-
nopausal women [14], and the activity level did not differ
between men and women. However, when the relationship
between PLTP activity and several lipid and metabolic
parameters was analyzed, a clear gender difference was
observed. In women but not in men, plasma PLTP activity
was positively correlated with apo B, total and LDL choles-
terol, triglyceride, and adiposity. The association of apo B,
LDL cholesterol, and adiposity with plasma PLTP activity
level confirms our previous observations in premenopausal
women [14]. The strong association of PLTP activity with
apo B level is consistent with a recent report showing that the
lack of PLTP in PLTP knock-out mice significantly reduces
apo B secretion, and that PLTP plays a role in regulating the
secretion of LpB [29].
Since PLTP activity showed the strongest relationship
with apo B, we wanted to know if this relationship occurred
with all LpB. Our data indicate that among the LpB, IDL and
buoyant LDL were most highly associated with plasma
PLTP activity. This relationship was initially evident only
in women. However, after the obese men were excluded,
PLTP activity was found to be significantly and positively
correlated with buoyant LDL. Thus, our failure to find a
significant correlation of PLTP with LpB in our earlier study
[30] likely relates to the fact that many of those men were
obese. Neither men nor women, whether lean or obese,
exhibited a significant correlation between PLTP and dense
LDL. These data suggest that PLTP activity is an important
determinant of buoyant LDL level. In contrast, plasma
factors other than PLTP, such as hepatic triglyceride lipase
(HL), may play a greater modulating function in the for-
mation of dense LDL [43]. Multiple linear regression anal-
ysis indicates that besides PLTP, plasma triglyceride is also a
significant determinant of IDL. This is consistent with the
known association of elevated IDL levels with hypertrigly-
ceridemia [44]. Interestingly, besides apo B, HDL or apo A-I
was a significant modulator of the plasma buoyant LDL level
in both men and women in this study population.
Although it is becoming clear that PLTP plays an
important role in the metabolism of both HDL and LpB, it
is important to note that active PTLP in plasma is associated
with a broad size range of HDL particles (7.6–12.0 nm),
with the major portion of active PLTP associated with HDL
particles of 9 to 12 nm, but little if any active PLTP is
associated with apo B-containing particles [45]. However,
inactive PLTP is found in association with large lipoprotein
particles (12 to >17 nm) containing apo B [45].
The importance of PLTP in triglyceride-rich lipoprotein
and HDL metabolism was first suggested by in vitro studies
showing that it can facilitate the transfer of surface lipids
from triglyceride-rich lipoproteins to HDL and can mediate
HDL conversion [1–5]. The relevance of these in vitro
observations to the in vivo situation however, has yet to be
clarified, as both deficiency [10] and overexpression of
PLTP [7,8] in mice result in low HDL levels. Our study
evaluating the relationship between PLTP and LpB sub-
fractions in humans suggests that PLTP activity may be an
important determinant of plasma IDL and buoyant LDL
levels and their relative distribution among other lipopro-
teins. While the association of PLTP with plasma apo B
level is consistent with its putative regulatory role in the
secretion of LpB [29], its association with the level and
distribution of IDL and buoyant LDL likely in part reflects
its lipid transfer function.
The gender differences observed in the association be-
tween PLTP and LpB in our subjects, e.g. a significant
positive association between PLTP and IDL in women but
not in men, suggests that other gender-related factors
modulate the impact of PLTP on these lipoproteins. This
observation is reminiscent of the report of Reardon et al.
[46], who found a marked gender difference in the relation-
ship between the severity of atherosclerosis and lipoprotein
parameters. In women, severity of atherosclerosis was
positively associated with IDL triglyceride, cholesterol and
apo B, and with total and LDL triglyceride, whereas in men,
it was positively associated with total and LDL cholesterol,
and apo B. This observation is in agreement with the current
view that triglyceride is a stronger risk factor for coronary
disease in women compared to men [47,48]. Of the lipid and
metabolic variables measured, the men and women in this
study differed significantly in BMI, IAF, Si, apo A-I, and in
HDL cholesterol (Table 1). Decreased insulin sensitivity and
increased IAF in men are likely associated with higher HL
activity relative to LPL activity [49,50] and may contribute
to the lower HDL observed. Hepatic lipase, which hydrol-
yses both triglyceride and phospholipid, also promotes the
formation of dense LDL [43]. Because PLTP is not signifi-
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cantly correlated with dense LDL, the relatively higher HL
activity in men may weaken the relationship between PLTP
and the LpB. As PLTP is significantly related to LpB in
premenopausal women and postmenopausal women on
hormone replacement therapy but not in postmenopausal
women not taking hormones, the stronger relationship
between PLTP and LpB observed in women as compared
to men may also relate to hormonal differences.
In summary, we have provided evidence that plasma
PLTP activity plays a role in LpB metabolism, particularly
IDL and buoyant LDL. The impact of PLTP on these
lipoproteins, however, can be modified by other factors,
some of which appear to be gender-related.
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